Vivos (RDGL) Return on Capital Employed (2011 - 2025)
Vivos' (RDGL) quarterly Return on Capital Employed came in at 161.19% in Q4 2025, down 361.0% year-on-year from 61.76% in Q4 2024, and down 42.99% quarter-over-quarter from 112.73% in Q3 2025.
Vivos (RDGL) Return on Capital Employed (2011 - 2025) Analysis & Trends
Vivos has disclosed Return on Capital Employed across 15 years of filings, most recently posting 161.19% for Q4 2025.
- Return on Capital Employed for Q4 2025 came in at 161.19%, down 361.0% year-over-year; the trailing twelve-month figure through Dec 2025 was 161.19% (down 361.0% YoY), and the FY2025 annual result was 163.77%, down 2189.0% from the prior year.
- Return on Capital Employed came in at 161.19% for Q4 2025 at Vivos, down from 112.73% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 75.62% in Q1 2021 to a low of 219.63% in Q1 2024.
- The 5-year median for Return on Capital Employed is 153.6% (2021), against an average of 156.53%.
- Across the five-year window, Return on Capital Employed slumped 31454 bps in 2021 and soared 11064 bps in 2025, its largest moves.
- Vivos' Return on Capital Employed stood at 149.62% in 2021, then grew by 7 bps to 138.89% in 2022, then plunged by 50 bps to 207.93% in 2023, then rose by 24 bps to 157.59% in 2024, then slipped by 2 bps to 161.19% in 2025.
- The last three Return on Capital Employed figures came in at 161.19% (Q4 2025), 112.73% (Q3 2025), and 103.43% (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | 9.61% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 12.24% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 7.36% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | 9.62% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | 11.13% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 10.45% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 24.24% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 9.30% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 11.57% |
| 10 | Vivos | - | - | -3,105.00 | -161.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -161.19% |
| Sep 30, 2025 | -112.73% |
| Jun 30, 2025 | -103.43% |
| Mar 31, 2025 | -108.99% |
| Dec 31, 2024 | -157.59% |
| Sep 30, 2024 | -197.88% |
| Jun 30, 2024 | -193.68% |
| Mar 31, 2024 | -219.63% |
| Dec 31, 2023 | -207.93% |
| Sep 30, 2023 | -162.73% |
| Jun 30, 2023 | -141.81% |
| Mar 31, 2023 | -129.96% |
| Dec 31, 2022 | -138.89% |
| Sep 30, 2022 | -143.38% |
| Jun 30, 2022 | -196.20% |
| Mar 31, 2022 | -217.54% |
| Dec 31, 2021 | -149.62% |
| Sep 30, 2021 | -169.77% |
| Jun 30, 2021 | -142.05% |
| Mar 31, 2021 | -75.62% |